3-year update from the KEYNOTE-942 trial: mRNA-4157 (V940) + pembrolizumab in resected melanoma

(1:5)

mRNA-4157, a novel mRNA vaccine, with pembrolizumab in melanoma

(3:10)

3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157 plus pembrolizumab ...

(1:28)

Unanswered questions in the use of mRNA-based personalized cancer vaccines

(1:39)

A personalized mRNA vaccine with pembrolizumab in melanoma

(4:10)

INTerpath-002: pembrolizumab with a neoantigen therapy in completely resected NSCLC

(1:21)

mRNA Cancer Vaccine

(12:42)

How mRNA cancer vaccines work

(1:3)

KEYNOTE-942: DMFS findings of a personalized mRNA vaccine in melanoma

(2:14)

Dr. Meredith McKean on mRNA Combined Immunotherapy for Melanoma – NBCLX

(6:11)

Navigating Cancer Immunotherapy: Exploring the World of mRNA Vaccines

(22:20)

Adding new vaccine type to leading immunotherapy dramatically reduced melanoma recurrence

(7:7)

Vaccine-immunotherapy combo for high risk melanoma: New data on distant metastasis-free survival

(4:5)

AACR 2023 highlights on advances in the treatment of resected high-risk melanoma with Jeffrey Weber

(3:40)

SITC 2024: Tiago Biachi MD PhD and CEO Patrick Hwu MD Discuss New Breakthroughs in Cancer Treatment

(3:45)

Breakthrough in Melanoma Treatment: mRNA-4157-P201.mp4

(1:2)

How mRNA could help fight deadly cancer | DW News

(7:4)

Neoantigen Vaccine With Pembrolizumab Has Clear Benefit in Resected Melanoma

(4:22)

Can personalized mRNA vaccines be applicable in lung cancer?

(59)

Highlights in melanoma at AACR 2023

(52)